What is the best treatment for malignant pleural effusions?

被引:30
作者
Zahid, Imran [2 ]
Routledge, Tom [1 ]
Bille, Andrea [1 ]
Scarci, Marco [1 ]
机构
[1] Guys Hosp, Dept Thorac Surg, London SE1 9RT, England
[2] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England
关键词
Pleural effusion; Malignant mesothelioma; Treatment; THORACOSCOPIC TALC PLEURODESIS; PLEUROPERITONEAL SHUNTS; MANAGEMENT; CATHETER; MESOTHELIOMA; MORBIDITY;
D O I
10.1510/icvts.2010.254789
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether chemical pleurodesis is superior to catheter drainage or pleuroperitoneal shunts (PPS) in the management of patients with pleural effusions. Overall 161 papers were found using the reported search, of which 14 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results are tabulated. We conclude that chemical pleurodesis is superior to chronic catheter drainage and PPS in terms survival length and mortality rates but in patients with trapped lung syndrome chronic intrapleural catheter placement is indicated. Six studies reported patient outcomes after treatment with chemical pleurodesis. They report high success rates (89.4%) and low mortality rates (2%) without any need to convert to open thoracotomy. Mean hospital stay of 2.33 days, complication rates of 16.5% and mean survival length of 23.8 +/- 16.3 months were observed. Five studies managed malignant pleural effusions (MPEs) using chronic indwelling catheters. They reported mean survival length of 126 days. Symptomatic relief was achieved in 94.2% of patients. There was a significant reduction in the Medical Research Council dyspnoea score (3.0-1.9, P<0.001) and despite complication rates of 22%, comparable mortality rates (7.5%) were observed. Even in patients with trapped lung syndrome, mean survival length was 125 days with symptomatic improvement being achieved in 90.9% of patients. Three studies treated MPEs using PPSs. Mean hospital stay was 6.2 days (range 2-26) with a mean survival length of 11 months. Pleurodesis success rates varied from 57.1% to 95% with a complication rate of 14.8%. PPSs were shown to produce lower success rates (57.1% vs. 92.3%), shorter survival lengths (4.3 +/- 1.9 vs. 6.7 +/- 2.1 months) and higher complication rates (14.3% vs. 2.8%) than talc pleurodesis. Overall, chemical pleurodesis is the optimal treatment option for MPE with use of chronic intrapleural catheters reserved in cases where talc pleurodesis is not possible. (C) 2011 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.
引用
收藏
页码:818 / 823
页数:6
相关论文
共 16 条
[1]   Prolonged survival after talc poudrage for malignant pleural mesothelioma: Case series [J].
Aelony, Y ;
Yao, JF .
RESPIROLOGY, 2005, 10 (05) :649-655
[2]   Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases [J].
Barbetakis, Nikolaos ;
Asteriou, Christos ;
Papadopoulou, Fani ;
Samanidis, Georgios ;
Paliouras, Dimitrios ;
Kleontas, Athanassios ;
Lyriti, Konstantina ;
Katsikas, Ioannis ;
Tsilikas, Christodoulos .
JOURNAL OF CARDIOTHORACIC SURGERY, 2010, 5
[3]   Ambulatory Intercostal Drainage for the Management of Malignant Pleural Effusion: A Single Center Experience [J].
Bazerbashi, Samer ;
Villaquiran, Jaime ;
Yousaf, Mohammad ;
Unsworth-White, Michael Jonathan ;
Rahamim, Joe ;
Marchbank, Adrian .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (12) :3482-3487
[4]  
Dunning Joel, 2003, Interact Cardiovasc Thorac Surg, V2, P405, DOI 10.1016/S1569-9293(03)00191-9
[5]   The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions [J].
Genc, O ;
Petrou, M ;
Ladas, G ;
Goldstraw, P .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2000, 18 (02) :143-146
[6]   Recent advances in the diagnosis and management of malignant pleural effusions [J].
Heffner, John E. ;
Klein, Jeffrey S. .
MAYO CLINIC PROCEEDINGS, 2008, 83 (02) :235-250
[7]   Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions [J].
Kolschmann, S ;
Ballin, A ;
Gillissen, A .
CHEST, 2005, 128 (03) :1431-1435
[8]   Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion [J].
Pien, GW ;
Gant, MJ ;
Washam, CL ;
Sterman, DH .
CHEST, 2001, 119 (06) :1641-1646
[9]  
Qureshi Rizwan A, 2008, Asian Cardiovasc Thorac Ann, V16, P120
[10]   Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study [J].
Rahman, Najib M. ;
Davies, Helen E. ;
Salzberg, Marc ;
Truog, Peter ;
Midgely, Rachel ;
Kerr, David ;
Clelland, Colin ;
Hedley, Emma L. ;
Lee, Y. C. Gary ;
Davies, Robert J. O. .
LANCET ONCOLOGY, 2008, 9 (10) :946-952